These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34242101)

  • 1. Improvements in the Tolerability Profile of 2'-
    Partridge W; Xia S; Kwoh TJ; Bhanot S; Geary RS; Baker BF
    Nucleic Acid Ther; 2021 Dec; 31(6):417-426. PubMed ID: 34242101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.
    Crooke ST; Baker BF; Witztum JL; Kwoh TJ; Pham NC; Salgado N; McEvoy BW; Cheng W; Hughes SG; Bhanot S; Geary RS
    Nucleic Acid Ther; 2017 Jun; 27(3):121-129. PubMed ID: 28145801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans.
    Crooke ST; Baker BF; Pham NC; Hughes SG; Kwoh TJ; Cai D; Tsimikas S; Geary RS; Bhanot S
    Nucleic Acid Ther; 2018 Feb; 28(1):10-22. PubMed ID: 29185862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events.
    Partridge W; Burel SA; Ferng A; Xia S; Kwoh TJ; Henry SP; Baker BF
    Clin Transl Sci; 2023 Apr; 16(4):575-580. PubMed ID: 36631935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Assessment of Phase 2 Data on GalNAc
    Baker BF; Xia S; Partridge W; Kwoh TJ; Tsimikas S; Bhanot S; Geary RS
    Nucleic Acid Ther; 2023 Jan; 33(1):72-80. PubMed ID: 36454263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
    Kim TW; Kim KS; Seo JW; Park SY; Henry SP
    J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates.
    Slingsby MHL; Vijey P; Tsai IT; Roweth H; Couldwell G; Wilkie AR; Gaus H; Goolsby JM; Okazaki R; Terkovich BE; Semple JW; Thon JN; Henry SP; Narayanan P; Italiano JE
    Haematologica; 2022 Feb; 107(2):519-531. PubMed ID: 33567808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
    Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
    Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
    Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists.
    Alharbi AS; Garcin AJ; Lennox KA; Pradeloux S; Wong C; Straub S; Valentin R; Pépin G; Li HM; Nold MF; Nold-Petry CA; Behlke MA; Gantier MP
    Nucleic Acids Res; 2020 Jul; 48(13):7052-7065. PubMed ID: 32544249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects.
    Yu RZ; Gunawan R; Geary RS; Hughes SG; Henry SP; Wang Y
    Nucleic Acid Ther; 2017 Oct; 27(5):285-294. PubMed ID: 28799823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-
    Pirie E; Cauntay P; Fu W; Ray S; Pan C; Lusis AJ; Hsiao J; Burel SA; Narayanan P; Crooke RM; Lee RG
    Nucleic Acid Ther; 2019 Oct; 29(5):266-277. PubMed ID: 31368839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.
    Koller E; Propp S; Zhang H; Zhao C; Xiao X; Chang M; Hirsch SA; Shepard PJ; Koo S; Murphy C; Glazer RI; Dean NM
    Cancer Res; 2006 Feb; 66(4):2059-66. PubMed ID: 16489005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers.
    Flaim JD; Grundy JS; Baker BF; McGowan MP; Kastelein JJ
    J Am Heart Assoc; 2014 Mar; 3(2):e000560. PubMed ID: 24627419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
    Alhamadani F; Zhang K; Parikh R; Wu H; Rasmussen TP; Bahal R; Zhong XB; Manautou JE
    Drug Metab Dispos; 2022 Jun; 50(6):879-887. PubMed ID: 35221289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.